Product Information
ZIPRASIDONE HCL 40 MG CAPSULE is a generic product labeled by Major Pharmaceuticals, priced at $0.2722 per EA under NDC 00904627045. Its NADAC has been published 386 times since May 15, 2019.
FDA first approved this application on Mar 2, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904627045
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ZIPRASIDONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077565FDA Approved
3/2/2012
TE Code
AB
On Market Since
3/15/2012
Pharmacological Classes
Price Statistics
The NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has been published 386 times since May 15, 2019, and over the history we have for it it has declined 24.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2722 per EA |
|---|---|
| All-time high | $0.4314 (Oct 14, 2020) |
| All-time low | $0.1879 (Nov 20, 2024) |
| 52-week high | $0.2786 |
| 52-week low | $0.2548 |
| Median price | $0.2867 |
| Average price | $0.2865 |
| Largest weekly change | +41.5% (Sep 23, 2020) |
| Weeks tracked | 386 |
| Tracking since | May 15, 2019 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ziprasidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZIPRASIDONE HCL 40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ZIPRASIDONE HCL 40 MG CAPSULE, manufactured by Major Pharmaceuticals, is $0.2722 per EA (NDC 00904627045), effective Sep 30, 2026.
How has the price of ZIPRASIDONE HCL 40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has declined 24.0%. It has been tracked across 386 weekly CMS publications since May 15, 2019.
What are the highest and lowest recorded NADAC prices for ZIPRASIDONE HCL 40 MG CAPSULE?
Since May 15, 2019, the NADAC for ZIPRASIDONE HCL 40 MG CAPSULE has ranged from a low of $0.1879 (Nov 20, 2024) to a high of $0.4314 (Oct 14, 2020), with a median of $0.2867 per EA.
Are there cheaper alternatives to ZIPRASIDONE HCL 40 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ZIPRASIDONE HCL 40 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ZIPRASIDONE HCL 40 MG CAPSULE?
ZIPRASIDONE HCL 40 MG CAPSULE (NDC 00904627045) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.